Cargando…

Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer

BACKGROUND: Ovarian carcinoma is one of the most common gynecologic malignancies, cisplatin resistance has become a key obstacle to the successful treatment of ovarian cancer because ovarian carcinomas are liable to drug resistance. To find an effective drug carrier is an urgent need. METHODS: Exoso...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Guannan, Gu, Yuanyuan, Zhu, Zhongyi, Zhang, Hongdao, Liu, Wei, Xu, Beiying, Zhou, Fangyue, Zhang, Menglei, Hua, Keqin, Wu, Ligang, Ding, Jingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113028/
https://www.ncbi.nlm.nih.gov/pubmed/35592860
http://dx.doi.org/10.3389/fmed.2022.810761
_version_ 1784709512164278272
author Zhou, Guannan
Gu, Yuanyuan
Zhu, Zhongyi
Zhang, Hongdao
Liu, Wei
Xu, Beiying
Zhou, Fangyue
Zhang, Menglei
Hua, Keqin
Wu, Ligang
Ding, Jingxin
author_facet Zhou, Guannan
Gu, Yuanyuan
Zhu, Zhongyi
Zhang, Hongdao
Liu, Wei
Xu, Beiying
Zhou, Fangyue
Zhang, Menglei
Hua, Keqin
Wu, Ligang
Ding, Jingxin
author_sort Zhou, Guannan
collection PubMed
description BACKGROUND: Ovarian carcinoma is one of the most common gynecologic malignancies, cisplatin resistance has become a key obstacle to the successful treatment of ovarian cancer because ovarian carcinomas are liable to drug resistance. To find an effective drug carrier is an urgent need. METHODS: Exosomes and loading-cisplatin exosomes are isolated using differential centrifugation and characterized by transmission, electron, nanoparticle tracking analysis. The anti-cancer effect of cisplatin was detected under the circumstance of delivered by exosomes or without exosomes in vitro and in vivo. Using proteome analysis and bioinformatics analysis, we further discovered the pathways in exosomes delivery process. We employed a con-focal immunofluorescence analysis, to evaluate the effects of milk-exosomes deliver the cisplatin via avoiding endosomal trapping. RESULTS: Exosomes and exosome-cisplatin were characterized including size, typical markers including CD63, Alix and Tsg101. The anti-cancer effect of cisplatin was enhanced when delivered by exosome in vitro and in vivo. Mechanistic studies shown that exosomes deliver cisplatin mostly via clathrin-independent endocytosis pathway. Exosomes deliver cisplatin into cisplatin-resistant cancer cells clathrin-independent endocytosis and enhance the anti-cancer effect through avoiding endosome trapping. CONCLUSION: Cisplatin could be delivered by exosome through clathrin-independent endocytosis, and could evade the endosome trapping, diffused in the cytosol evenly. Our study clarifies the mechanism of exosomes mediated drug delivery against resistant cancer, indicates that exosomes can be a potential nano-carrier for cisplatin against cisplatin resistant ovarian cancer, which validates and enriches the theory of intracellular exosome trafficking.
format Online
Article
Text
id pubmed-9113028
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91130282022-05-18 Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer Zhou, Guannan Gu, Yuanyuan Zhu, Zhongyi Zhang, Hongdao Liu, Wei Xu, Beiying Zhou, Fangyue Zhang, Menglei Hua, Keqin Wu, Ligang Ding, Jingxin Front Med (Lausanne) Medicine BACKGROUND: Ovarian carcinoma is one of the most common gynecologic malignancies, cisplatin resistance has become a key obstacle to the successful treatment of ovarian cancer because ovarian carcinomas are liable to drug resistance. To find an effective drug carrier is an urgent need. METHODS: Exosomes and loading-cisplatin exosomes are isolated using differential centrifugation and characterized by transmission, electron, nanoparticle tracking analysis. The anti-cancer effect of cisplatin was detected under the circumstance of delivered by exosomes or without exosomes in vitro and in vivo. Using proteome analysis and bioinformatics analysis, we further discovered the pathways in exosomes delivery process. We employed a con-focal immunofluorescence analysis, to evaluate the effects of milk-exosomes deliver the cisplatin via avoiding endosomal trapping. RESULTS: Exosomes and exosome-cisplatin were characterized including size, typical markers including CD63, Alix and Tsg101. The anti-cancer effect of cisplatin was enhanced when delivered by exosome in vitro and in vivo. Mechanistic studies shown that exosomes deliver cisplatin mostly via clathrin-independent endocytosis pathway. Exosomes deliver cisplatin into cisplatin-resistant cancer cells clathrin-independent endocytosis and enhance the anti-cancer effect through avoiding endosome trapping. CONCLUSION: Cisplatin could be delivered by exosome through clathrin-independent endocytosis, and could evade the endosome trapping, diffused in the cytosol evenly. Our study clarifies the mechanism of exosomes mediated drug delivery against resistant cancer, indicates that exosomes can be a potential nano-carrier for cisplatin against cisplatin resistant ovarian cancer, which validates and enriches the theory of intracellular exosome trafficking. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9113028/ /pubmed/35592860 http://dx.doi.org/10.3389/fmed.2022.810761 Text en Copyright © 2022 Zhou, Gu, Zhu, Zhang, Liu, Xu, Zhou, Zhang, Hua, Wu and Ding. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zhou, Guannan
Gu, Yuanyuan
Zhu, Zhongyi
Zhang, Hongdao
Liu, Wei
Xu, Beiying
Zhou, Fangyue
Zhang, Menglei
Hua, Keqin
Wu, Ligang
Ding, Jingxin
Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer
title Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer
title_full Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer
title_fullStr Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer
title_full_unstemmed Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer
title_short Exosome Mediated Cytosolic Cisplatin Delivery Through Clathrin-Independent Endocytosis and Enhanced Anti-cancer Effect via Avoiding Endosome Trapping in Cisplatin-Resistant Ovarian Cancer
title_sort exosome mediated cytosolic cisplatin delivery through clathrin-independent endocytosis and enhanced anti-cancer effect via avoiding endosome trapping in cisplatin-resistant ovarian cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113028/
https://www.ncbi.nlm.nih.gov/pubmed/35592860
http://dx.doi.org/10.3389/fmed.2022.810761
work_keys_str_mv AT zhouguannan exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT guyuanyuan exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT zhuzhongyi exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT zhanghongdao exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT liuwei exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT xubeiying exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT zhoufangyue exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT zhangmenglei exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT huakeqin exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT wuligang exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer
AT dingjingxin exosomemediatedcytosoliccisplatindeliverythroughclathrinindependentendocytosisandenhancedanticancereffectviaavoidingendosometrappingincisplatinresistantovariancancer